Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:activities |
immune checkpoint inhibitor
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:legislation
gptkb:2017 gptkb:FDA gptkb:United_States |
| gptkbp:can_be_used_with |
radiation therapy
chemotherapy |
| gptkbp:clinical_trial |
gptkb:PACIFIC_trial
Phase III NC T01693562 ARCTIC trial NC T02516241 |
| gptkbp:combatants |
high affinity for PD-L1
|
| gptkbp:contraindication |
active autoimmune disease
history of severe hypersensitivity concurrent live vaccines |
| gptkbp:developed_by |
gptkb:temple
|
| gptkbp:dosage_form |
solution for infusion
|
| gptkbp:financial_performance |
stable for 24 hours at room temperature after dilution
|
| gptkbp:frequency |
every 2 weeks
|
| https://www.w3.org/2000/01/rdf-schema#label |
durvalumab
|
| gptkbp:indication |
unresectable stage III non-small cell lung cancer
locally advanced or metastatic urothelial carcinoma |
| gptkbp:ingredients |
C6424 H9924 N1716 O1980 S44
|
| gptkbp:invention |
patented
|
| gptkbp:is_monitored_by |
immune-related adverse events
|
| gptkbp:is_used_for |
treatment of bladder cancer
treatment of non-small cell lung cancer |
| gptkbp:lifespan |
approximately 15 days
|
| gptkbp:manager |
IV
|
| gptkbp:marketed_as |
gptkb:Imfinzi
|
| gptkbp:pharmacokinetics |
linear pharmacokinetics
inhibits PD-L1 binding to PD-1 and C D80 |
| gptkbp:research_focus |
biomarker identification
combination therapies long-term outcomes patient selection treatment sequencing |
| gptkbp:rounds |
hepatic metabolism
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
fatigue
nausea diarrhea rash immune-related adverse events pneumonitis |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
gptkb:PD-L1
|
| gptkbp:traded_on |
gptkb:Imfinzi
|
| gptkbp:weight |
150 k Da
|
| gptkbp:bfsParent |
gptkb:Imfinzi
|
| gptkbp:bfsLayer |
4
|